Objective: Interstitial lung disease associated with gefitinib is a critical adverse reaction. When geftinib was administered to EGFR-unknown patients, the interstitial lung disease incidence rate was approximately 3 -4% in Japan, and usually occurs during the first 4 weeks of treatment. However, it has not been fully investigated in EGFR-mutated patients. Methods: We collected clinical records of participants of two Phase III trials (WJTOG 3405 and NEJ 002), which compared gefitinib with platinum doublet chemotherapy. All patients were EGFR mutated, chemo-naïve and had good performance status. Results: A total of 402 patients were enrolled in this study. In the gefitinib arm, 10 (5.0%) of 201 patients developed interstitial lung disease, of whom five (2.5%) were Grade 3 or greater, with two deaths (1.0%). In contrast, only one patient developed interstitial lung disease (Grade 1) in the chemotherapy arm. With regard to gefitinib, smoking history was significantly associated with developing interstitial lung disease (odds ratio 0.18; 95% confidence interval: 0.05 -0.74; P ¼ 0.01). The cumulative incidence rate of interstitial lung disease was similar in the 0 -4, 5 -8 and 9 -12 week time periods. However, between smokers and never-smokers, cumulative incidence rates in the first 4 weeks were significantly different (4.7% versus 0%, P ¼ 0.03). Three of 10 patients developed interstitial lung disease after 8 weeks of gefitinib administration (days 135, 171 and 190, respectively). Conclusions: Among EGFR-mutated patients, the incidence of interstitial lung disease associated with gefitinib was not different from that in previous reports. Smoking history was associated with developing interstitial lung disease, and smokers had a higher incidence rate of interstitial lung disease in the first 4 weeks.
INTRODUCTION
The recent introduction of targeted agents has dramatically changed the treatment of non-small-cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is a prototype of such therapy which targets NSCLC harboring the EGFR mutation (1, 2) . EGFR-TKIs have demonstrated a higher response rate and longer progression-free survival than platinum doublet chemotherapy (3 -6) . Common adverse events associated with EGFR-TKIs include skin rash, diarrhea and hepatotoxicity. Interstitial lung disease (ILD) is a rare but potentially fatal adverse event (7) . The incidence of ILD has been reported to be higher in Japanese than in Caucasians. Two large, multi-institutional studies in Japan (8 -10) reported that its incidence is 3.5 -4.0%, compared with just 0.3% in the USA (11) . They also suggested that male gender, history of smoking, poor performance status, pre-existing lung disorder and prior history of chemotherapy were predictive risk factors (8 -10) .
Today, clinical guidelines recommend that administration of EGFR-TKIs should be limited to EGFR-mutated patients, reflecting the high efficacy of this drug in this patient population (12) . Since it is known that EGFR mutation is relatively rare in males or smokers, which are known risk factors of ILD, ILD incidence might be lower in patients with EGFR mutation. However, a detailed investigation of ILD associated with EGFR-TKIs among EGFR-mutated patients has not been done. Therefore, we conducted a combined analysis of two Phase III trials that compared gefitinib with platinum doublet chemotherapy in Japanese NSCLC patients with EGFR mutation.
PATIENTS AND METHODS

PATIENT SELECTION AND TREATMENT METHODS
We collected the clinical records of participants of two Phase III trials (WJTOG 3405 (3) and NEJ 002 (4)). These trials compared gefitinib with platinum doublet chemotherapy in Japanese NSCLC patients with EGFR mutation. EGFR mutation was screened by PCR-based methods as previously described (13, 14) . All of the participants were required to be chemo-naïve, with Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 -1 and aged between 20 and 75 years, with adequate organ function. Patients with active infectious disease or severe heart disease were excluded. All patients were confirmed not to have pulmonary fibrosis by chest computed tomography (CT) within 1 month prior to registration. Both studies were approved by the institutional review board at each participating site.
Eligible patients were randomly assigned to receive either gefitinib (250 mg daily) or standard chemotherapy. All patients were assessed by chest CT for their response to treatment every 2 months. The diagnosis of ILD was based on clinical manifestations (worsening dry cough or dyspnea within days to weeks), accompanied by interstitial pulmonary infiltrates on a chest X-ray and a chest CT (15) . Close investigation, such as blood and bacterial examination, was required in the protocols to exclude other ILDs. Bronchoalveolar lavage was also recommended, if possible. ILD was assessed according to the National Cancer Institute Table 1 . Baseline characteristics of the patients in the gefitinib arm Common Terminology Criteria (NCI-CTC, version 3.0). All events were assessed by investigators at first; then severe cases were confirmed by independent committees based on medical, pathological and radiological findings. Differences between covariates in patients with or without ILD were analyzed using Fisher's exact tests or Pearson's tests. The Kaplan -Meier method was used to estimate the cumulative incidence rate of ILD, and differences according to the smoking status were analyzed by the log-rank test. All the analyses were performed using JMP version 7 (SAS Institute Inc., USA).
RESULTS
In WJOG 3405, 177 patients were randomized and 175 were included in the safety analysis. In NEJ 002, 230 patients were randomized and 227 were included in the safety analysis. In our study a total of 402 patients were enrolled, half of them in the gefitinib arm.
Baseline characteristics of the patients were well balanced between the treatment groups. As previously reported (3, 4) , about two-thirds of patients were female, the median age was 64 years, 65% were never-smokers, 55% had an ECOG PS of 0 and 95% had adenocarcinoma.
At the time of data cut-off, the median duration of gefitinib treatment was 165 days (WJTOG 3405) and 308 days (NEJ 002); the median number of chemotherapy cycles was four. In the gefitinib arm, 10 (5.0%) of 201 patients developed ILD, of whom five (2.5%) were Grade 3 or greater, with two deaths (1.0%). In contrast, only one patient developed ILD (Grade 1) in the chemotherapy arm.
The background and clinical course of the patients in the gefitinib arm are summarized in Tables 1 and 2 . The clinical background of patients who developed ILD and those who did not showed no difference other than smoking status.
Univariate analysis showed that smoking history was significantly associated with developing ILD (odds ratio 0.18; 95% confidence interval (CI): 0.05 -0.74; P ¼ 0.01). This accounted for 10.9% (95% CI: 5.4 -20.9%) of the incidence rate of ILD among smokers, versus 2.2% (95% CI: 0.8 -6.3%) among never-smokers. Figure 1 shows a Kaplan -Meier curve of the cumulative incidence rate of ILD. Among the overall population, the cumulative incidence rate in the first 4 weeks, 5th -8th weeks and 9th -12th weeks was 1.5% (95% CI: 0.5 -4.3%), 1.5% (95% CI: 0.5 -4.4%) and 0.5% (95% CI: 0.1 -2.9%), respectively. Smoking status was associated with the timing of the onset of ILD . Between smokers and never-smokers, the cumulative incidence rate of ILD in the first 4 weeks was significantly different (4.7 versus 0%, P ¼ 0.03), whereas that in the other periods (5th -8th weeks and 9th -12th weeks) was similar (Fig. 1) . Three of 10 patients developed ILD after 8 weeks of gefitinib administration (days 135, 171 and 190, respectively).
Most of the patients who developed severe ILD (Gr 3) were given steroid therapy. One patient was treated with an immunosuppressive agent (cyclosporine). Non-invasive positive pressure ventilation was used in one patient (No. 10) but unfortunately this patient died.
DISCUSSION
Three large studies of ILD associated with EGFR-TKI have been conducted in Japan (Table 3) . Ando et al. (8) performed a retrospective study including 1976 NSCLC patients treated with gefitinib and found an incidence rate of 3.5% and mortality rate of 1.6%. In a prospective cohort and nested-case control study by Kudoh et al. (9) , cumulative incidence rates during 12 weeks of treatment were 4.0%. They also mentioned that the risk of developing ILD was higher 
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ILD associated with gefitinib in EGFR-mutated patients with gefitinib than with chemotherapy (the odds ratio was 3.2). With regard to erlotinib, Nakagawa et al. (10) conducted a post-marketing survey in Japan and reported that 158 of 3488 patients were confirmed to have ILD (any grade, 4.5%), with a mortality rate of 1.6%. These studies suggested that male gender, smoking history, poor PS, preexisting lung disorder and prior history of chemotherapy were risk factors of ILD. However, none of the three studies mentioned EGFR mutation status. To our knowledge, ours is the first study to describe the clinical characteristics of ILD associated with gefitinib limited to EGFR-mutated patients. Similar to Kudoh's report, ILD was relatively more common in the gefitinib arm than in the chemotherapy arm. The incidence rate of ILD associated with gefitinib was as high as 5% with a mortality rate of 2.5%, even though our analysis contained a high proportion of patients from low-risk groups (female, nonsmokers with good PS).
Similarly to the previous studies, our analysis showed that smoking history was highly associated with developing ILD associated with gefitinib (odds ratio 0.18). Smoking induces airway epithelial damage, and lung injury could be prolonged and worsened by gefitinib in a preclinical model (16) . Most of the other risk factors were excluded at the time of registration, because enrolled patients were required to be chemo-naïve, with a PS of 0 -1, and confirmed not to have pulmonary fibrosis. Therefore, we should pay more attention to smoking status even if the patient has EGFR mutation. In terms of the timing of the onset of ILD, smoking history seemed to be an important factor. Between smokers and never-smokers, the cumulative incidence rate of ILD in the first 4 weeks was significantly different (4.7 versus 0%, P ¼ 0.03). Previous studies stated that ILD occurred most commonly in the first 4 weeks (median: 23 -31 days) and 60% of participants were smokers. So, despite the small subset analysis in the present study, the higher incidence rate observed in the first 4 weeks among smokers is noteworthy.
Another point is that three of 10 patients developed ILD after several months of gefitinib treatment. With erlotinib, it was reported that ILD occurred at the rate of 0.11 per 100 patient-weeks after 8 weeks of treatment. It is not clear whether the mechanism of ILD varies over time from its onset; further investigation on late-onset ILD is needed.
Our analysis has several limitations. First, this was an investigator-dependent analysis. Most of the ILD cases were diagnosed by clinical manifestations and a chest CT. Bronchoalveolar lavage was recommended in the protocols, but actually done in only one case. As acute exacerbation of ILD after bronchoscopy has been reported (15) , this may be acceptable. In our analysis, all patients were assessed by chest CT every 2 months, and severe cases were confirmed by independent, multidisciplinary committees. Secondly, this analysis was done with a small sample size due to the population and rarity of incidence. Figure 1 . Cumulative incidence rate of interstitial lung disease associated with gefitinib. Kaplan -Meier-estimated cumulative incidence rate of interstitial lung disease in patients who were allocated to the gefitinib arm in WJTOG 3405 and NEJ 002 trial (overall population (n ¼ 201), bold line; smoker (n ¼ 64), dashed line; non-smoker (n ¼ 137), dotted line).
In conclusion, the incidence of ILD associated with gefitinib among EGFR-mutated patients was not different from that in previous reports. Smoking history was highly associated with developing ILD. In addition, a substantial number of patients developed ILD after several months of gefitinib treatment.
